258 related articles for article (PubMed ID: 38514625)
1. Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma.
Ang DA; Carter JM; Deka K; Tan JHL; Zhou J; Chen Q; Chng WJ; Harmston N; Li Y
Nat Commun; 2024 Mar; 15(1):2513. PubMed ID: 38514625
[TBL] [Abstract][Full Text] [Related]
2. Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway.
Roy P; Mukherjee T; Chatterjee B; Vijayaragavan B; Banoth B; Basak S
Oncogene; 2017 Mar; 36(10):1417-1429. PubMed ID: 27641334
[TBL] [Abstract][Full Text] [Related]
3. NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression.
Sim N; Li Y
Commun Biol; 2023 Apr; 6(1):445. PubMed ID: 37087499
[TBL] [Abstract][Full Text] [Related]
4. A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.
de Oliveira KA; Kaergel E; Heinig M; Fontaine JF; Patone G; Muro EM; Mathas S; Hummel M; Andrade-Navarro MA; Hübner N; Scheidereit C
Genome Med; 2016 Mar; 8(1):28. PubMed ID: 26988706
[TBL] [Abstract][Full Text] [Related]
5. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Annunziata CM; Davis RE; Demchenko Y; Bellamy W; Gabrea A; Zhan F; Lenz G; Hanamura I; Wright G; Xiao W; Dave S; Hurt EM; Tan B; Zhao H; Stephens O; Santra M; Williams DR; Dang L; Barlogie B; Shaughnessy JD; Kuehl WM; Staudt LM
Cancer Cell; 2007 Aug; 12(2):115-30. PubMed ID: 17692804
[TBL] [Abstract][Full Text] [Related]
6. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Keats JJ; Fonseca R; Chesi M; Schop R; Baker A; Chng WJ; Van Wier S; Tiedemann R; Shi CX; Sebag M; Braggio E; Henry T; Zhu YX; Fogle H; Price-Troska T; Ahmann G; Mancini C; Brents LA; Kumar S; Greipp P; Dispenzieri A; Bryant B; Mulligan G; Bruhn L; Barrett M; Valdez R; Trent J; Stewart AK; Carpten J; Bergsagel PL
Cancer Cell; 2007 Aug; 12(2):131-44. PubMed ID: 17692805
[TBL] [Abstract][Full Text] [Related]
7. Activation of the non-canonical NF-κB/p52 pathway in vascular endothelial cells by RANKL elicits pro-calcific signalling in co-cultured smooth muscle cells.
Harper E; Rochfort KD; Forde H; Davenport C; Smith D; Cummins PM
Cell Signal; 2018 Jul; 47():142-150. PubMed ID: 29678621
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
[TBL] [Abstract][Full Text] [Related]
9. SCF-mediated degradation of p100 (NF-κB2): mechanisms and relevance in multiple myeloma.
Busino L; Millman SE; Pagano M
Sci Signal; 2012 Dec; 5(253):pt14. PubMed ID: 23211527
[TBL] [Abstract][Full Text] [Related]
10. A role of both NF-κB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells.
Shen X; Zhu W; Zhang X; Xu G; Ju S
Mol Cell Biochem; 2011 Nov; 357(1-2):21-30. PubMed ID: 21607696
[TBL] [Abstract][Full Text] [Related]
11. Immune Differentiation Regulator p100 Tunes NF-κB Responses to TNF.
Chatterjee B; Roy P; Sarkar UA; Zhao M; Ratra Y; Singh A; Chawla M; De S; Gomes J; Sen R; Basak S
Front Immunol; 2019; 10():997. PubMed ID: 31134075
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway.
Eliopoulos AG; Caamano JH; Flavell J; Reynolds GM; Murray PG; Poyet JL; Young LS
Oncogene; 2003 Oct; 22(48):7557-69. PubMed ID: 14576817
[TBL] [Abstract][Full Text] [Related]
13. Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.
Li Y; Zhou QL; Sun W; Chandrasekharan P; Cheng HS; Ying Z; Lakshmanan M; Raju A; Tenen DG; Cheng SY; Chuang KH; Li J; Prabhakar S; Li M; Tergaonkar V
Nat Cell Biol; 2015 Oct; 17(10):1327-38. PubMed ID: 26389665
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC
Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.
Dash AB; Zhang J; Shen L; Li B; Berg D; Lin J; Avet-Loiseau H; Bahlis NJ; Moreau P; Richardson PG; Di Bacco A
Eur J Haematol; 2020 Sep; 105(3):274-285. PubMed ID: 32350909
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.
Vallabhapurapu SD; Noothi SK; Pullum DA; Lawrie CH; Pallapati R; Potluri V; Kuntzen C; Khan S; Plas DR; Orlowski RZ; Chesi M; Kuehl WM; Bergsagel PL; Karin M; Vallabhapurapu S
Nat Commun; 2015 Oct; 6():8428. PubMed ID: 26455434
[TBL] [Abstract][Full Text] [Related]
17. Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence.
Iannetti A; Ledoux AC; Tudhope SJ; Sellier H; Zhao B; Mowla S; Moore A; Hummerich H; Gewurz BE; Cockell SJ; Jat PS; Willmore E; Perkins ND
PLoS Genet; 2014 Sep; 10(9):e1004642. PubMed ID: 25255445
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional Regulation during Aberrant Activation of NF-κB Signalling in Cancer.
Deka K; Li Y
Cells; 2023 Mar; 12(5):. PubMed ID: 36899924
[TBL] [Abstract][Full Text] [Related]
19. NF-κB dysregulation in multiple myeloma.
Matthews GM; de Matos Simoes R; Dhimolea E; Sheffer M; Gandolfi S; Dashevsky O; Sorrell JD; Mitsiades CS
Semin Cancer Biol; 2016 Aug; 39():68-76. PubMed ID: 27544796
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1.
Xu X; Li Y; Bharath SR; Ozturk MB; Bowler MW; Loo BZL; Tergaonkar V; Song H
Nat Commun; 2018 Aug; 9(1):3183. PubMed ID: 30093619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]